COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff

Sponsor
Herlev Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04346186
Collaborator
Nordsjaellands Hospital (Other), Hvidovre University Hospital (Other), Rigshospitalet, Denmark (Other), Mental Health Services in the Capital Region, Denmark (Other), University Hospital Bispebjerg and Frederiksberg (Other)
44,698
14
5.7
3192.7
555.3

Study Details

Study Description

Brief Summary

During the COVID-19 pandemic several countries have seen a high risk of transmission for health care personnel, with some countries having as many 20-25% of nurses and doctors either infected or showing symptoms of COVID-19.

In this prospective cohort study, we will systematically screen all hospital staff in the Capital Region of Denmark for IgM and IgG antibodies against SARS-CoV-2 using a point of care tests and an Elisa kit.

Testing will be offered 3 times: In April 2020, Maj 2020 and September 2020. All participants will submit a questionnaire regarding exposures, risk factors and symptoms of COVID-19 in relation to each testing. Follow-up will be through electronic patient records and national registries.

We will compare the group of health care personnel with data from a control group of healthy volunteer blood donors from the Danish Blood Donor Study.

The aim of the study is to investigate the proportion of hospital staff with SARS-CoV-2 antibodies during the study period compared to a control group representing the Danish population. We will compare the test characteristics of the two methods of testing, a point of care test and Elisa.

Further, we will investigate the extent to which prior immunization or infection is protective for future infection with COVID-19.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2
  • Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2

Study Design

Study Type:
Observational
Actual Enrollment :
44698 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff
Actual Study Start Date :
Apr 15, 2020
Actual Primary Completion Date :
Oct 7, 2020
Actual Study Completion Date :
Oct 7, 2020

Arms and Interventions

Arm Intervention/Treatment
Hospital Staff in the Capital Region of Denmark

Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2
Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2

Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2
Elisa-test for IgM and IgG to SARS-CoV-2

Healthy volunteer blood donors

Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2
Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2

Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2
Elisa-test for IgM and IgG to SARS-CoV-2

Outcome Measures

Primary Outcome Measures

  1. Positive IgM/IgG tests [At inclusion]

    Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population

  2. Positive IgM/IgG tests [1 month]

    Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population

  3. Positive IgM/IgG tests [5 month]

    Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population

  4. Comparison of the point of care test and Elisa [At inclusion]

    Comparison of the resultat from the point of care test and with results from Elisa

  5. Comparison of the point of care test and Elisa [1 months]

    Comparison of the resultat from the point of care test and with results from Elisa

  6. Comparison of the point of care test and Elisa [5 months]

    Comparison of the resultat from the point of care test and with results from Elisa

  7. Re-infection rate [180 days]

    Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19

  8. Re-infection rate [360 days]

    Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19

  9. IgM/IgG positive participants on follow-up test [1 month]

    Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up

  10. IgM/IgG positive participants on follow-up test [5 months]

    Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • 18 years old

  • Consent to participation

  • Employed at a Hospital in the Capitial Region of Denmark

Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 Herlev Hospital Herlev Region Hovedstaden Denmark 2730
2 Bispebjerg Hospital København NV Region Hovedstaden Denmark 2400
3 Psykiatrisk Center Ballerup Ballerup Denmark 2750
4 Psykiatrisk Center København Copenhagen Denmark 2100
5 Rigshospitalet Copenhagen Denmark 2100
6 Psykiatrisk Center Amager Copenhagen Denmark 2300
7 Psykiatrisk Center Stolpegaard Gentofte Denmark 2820
8 Børne- og Ungdomspsykiatrisk Center Glostrup Denmark 2600
9 Psykiatrisk Center Glostrup Glostrup Denmark 2700
10 Nordsjaellands Hospital Hillerød Denmark 3400
11 Psykiatrisk Center Nordsjælland Hillerød Denmark 3400
12 Psykiatrisk Center Sankt Hans Roskilde Denmark 4000
13 Bornholms Hospital Rønne Denmark 3700
14 Psykiatrisk Center Bornholm Rønne Denmark 3700

Sponsors and Collaborators

  • Herlev Hospital
  • Nordsjaellands Hospital
  • Hvidovre University Hospital
  • Rigshospitalet, Denmark
  • Mental Health Services in the Capital Region, Denmark
  • University Hospital Bispebjerg and Frederiksberg

Investigators

  • Principal Investigator: Kasper Iversen, Prof., Herlev-Gentofte Hospital
  • Principal Investigator: Henning Bundgaard, Prof., Rigshospitalet, Denmark
  • Principal Investigator: Henrik Ullum, Prof., Rigshospitalet, Denmark
  • Principal Investigator: Thomas Benfield, Prof., Hvidovre University Hospital
  • Principal Investigator: Susanne Dam Poulsen, Prof., Rigshospitalet, Denmark
  • Principal Investigator: Jørgen Rungby, Prof., Bispebjerg Hospital
  • Principal Investigator: Fredrik Folke, Associate prof., Akutberedskabet
  • Principal Investigator: Thea Kølsen Fischer, Nordsjællands Hospital
  • Principal Investigator: Ove Andersen, Prof., Hvidovre University Hospital
  • Principal Investigator: Ida Hageman, Mental Health Services in the Capital Region, Denmark

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kasper Iversen, Professor, Herlev Hospital
ClinicalTrials.gov Identifier:
NCT04346186
Other Study ID Numbers:
  • RegHCOVIDScreening
First Posted:
Apr 15, 2020
Last Update Posted:
Aug 25, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2022